Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk
According to the latest international and Russian guidelines for the treatment of dyslipidemias, statins are defined as the main group of drugs that significantly reduce the level of low-density lipoprotein cholesterol (LDL-C) effectively prevent atherosclerotic cardiovascular diseases (CVD) and com...
Saved in:
Published in | Aterotromboz (Online) Vol. 11; no. 2; pp. 56 - 75 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English Russian |
Published |
REMEDIUM GROUP» Ltd
21.01.2022
|
Subjects | |
Online Access | Get full text |
ISSN | 2307-1109 2658-5952 2658-5952 |
DOI | 10.21518/2307-1109-2021-11-2-56-75 |
Cover
Abstract | According to the latest international and Russian guidelines for the treatment of dyslipidemias, statins are defined as the main group of drugs that significantly reduce the level of low-density lipoprotein cholesterol (LDL-C) effectively prevent atherosclerotic cardiovascular diseases (CVD) and complications and can slow down the progression of atherosclerosis. The principle “the lower LDL-C, the better” is especially relevant in categories of patients with very high and extreme cardiovascular risk, and therefore, in order to achieve target LDL-C values (≤1.4 is optimal ≤1.0) in this category of patients, high-intensity lipid-lowering therapy should be used. Rosuvastatin remains the most effective statin. Its use makes possible to achieve target lipid values at the starting dose of treatment, enhances adherence to treatment, and also reduces the frequency of side effects associated with the use of high doses of other statins. In addition, the proven ability of rosuvastatin to reduce the volume of atherosclerotic plaque, by reducing the level of pro-inflammatory cytokines and C-reactive protein, normalizing endothelial function, antiplatelet action, that is, rosuvastatin, in addition to its powerful lipid-lowering effect, has anti-inflammatory and anti-ischemic effects. Also, rosuvastatin can be successfully used in the presence of comorbidities, including chronic kidney disease and chronic heart failure. Taking into consideration the urgency of the fight against the COVID-19 pandemic (coronavirus Disease 2019), which covered 220 countries, due to the lack of effective etiotropic drugs, the possibility of using statins, including rosuvastatin, for the treatment of comorbid patients with COVID-19, was evaluated. |
---|---|
AbstractList | According to the latest international and Russian guidelines for the treatment of dyslipidemias, statins are defined as the main group of drugs that significantly reduce the level of low-density lipoprotein cholesterol (LDL-C) effectively prevent atherosclerotic cardiovascular diseases (CVD) and complications and can slow down the progression of atherosclerosis. The principle “the lower LDL-C, the better” is especially relevant in categories of patients with very high and extreme cardiovascular risk, and therefore, in order to achieve target LDL-C values (≤1.4 is optimal ≤1.0) in this category of patients, high-intensity lipid-lowering therapy should be used. Rosuvastatin remains the most effective statin. Its use makes possible to achieve target lipid values at the starting dose of treatment, enhances adherence to treatment, and also reduces the frequency of side effects associated with the use of high doses of other statins. In addition, the proven ability of rosuvastatin to reduce the volume of atherosclerotic plaque, by reducing the level of pro-inflammatory cytokines and C-reactive protein, normalizing endothelial function, antiplatelet action, that is, rosuvastatin, in addition to its powerful lipid-lowering effect, has anti-inflammatory and anti-ischemic effects. Also, rosuvastatin can be successfully used in the presence of comorbidities, including chronic kidney disease and chronic heart failure. Taking into consideration the urgency of the fight against the COVID-19 pandemic (coronavirus Disease 2019), which covered 220 countries, due to the lack of effective etiotropic drugs, the possibility of using statins, including rosuvastatin, for the treatment of comorbid patients with COVID-19, was evaluated. |
Author | Ezhov, M. V. Alekseeva, I. A. Kolmakova, T. E. Tmoyan, N. A. |
Author_xml | – sequence: 1 givenname: T. E. orcidid: 0000-0002-0316-2940 surname: Kolmakova fullname: Kolmakova, T. E. organization: National Medical Research Center of Cardiology – sequence: 2 givenname: I. A. orcidid: 0000-0001-9685-4569 surname: Alekseeva fullname: Alekseeva, I. A. organization: National Medical Research Center of Cardiology – sequence: 3 givenname: N. A. orcidid: 0000-0002-3617-9343 surname: Tmoyan fullname: Tmoyan, N. A. organization: National Medical Research Center of Cardiology – sequence: 4 givenname: M. V. orcidid: 0000-0002-1518-6552 surname: Ezhov fullname: Ezhov, M. V. organization: National Medical Research Center of Cardiology |
BookMark | eNqVkU9PHSEUxUljk6r1OxD3VOAN_-yqMWpNTNzYNbnDgI92hAnMe2Y-Rr9xmffa7l1xAuf8bi7nDJ2knDxCl4x-4UwwfcU3VBHGqCGcctYU4URIosQHdMql0EQYwU-a_uf7hC5qjT3lSnMjO3GKft-GEF30yS04B7yNL1sS0-xTjfOC560vMC34Lc5bXHLd7aHOMMeEQy64epfTAGXBU_F7n-aY0wpxUIaYm9XtRijY5ddpjA7W54pbdmqyuesRC3jvG2KdjEusvz6jjwHG6i_-nufox93t88138vh0_3Dz7ZE4Jo0gZhiYpIErrgdGKXXSqI2jvQDfe6oluI5R0F0vgzDU91wI1ctOgzOOKdVvztHDkTtk-GmnEl_bJjZDtIeLXF4slDm60VsJQL3hSjituzZPd8x7YyCIjZRamsb6emTt0gTLG4zjfyCj9lCWXUuwawl2Laspy62QVomWvj6mXfviWnx4T_gPJAWesA |
Cites_doi | 10.1093/eurheartj/ehz455 10.1001/jama.291.9.1071 10.1093/ehjcvp/pvw006 10.21518/2079-701X-2020-14-26-32 10.1185/030079903125002405 10.1056/NEJMoa0706201 10.1093/eurheartj/ehw272 10.1016/j.ijcard.2008.06.055 10.1016/j.jacc.2005.03.077 10.1016/S0140-6736(05)67394-1 10.1097/HJR.0b013e3283316ce8 10.1016/j.amjcard.2020.08.004 10.1056/NEJMoa0810177 10.1007/s11239-014-1142-x 10.1007/s11883-014-0420-6 10.1016/j.jacc.2005.04.064 10.1016/j.acvd.2008.05.010 10.15829/1728-8800-2016-4-29-37 10.1056/NEJMoa1110874 10.1007/s10557-010-6224-1 10.1016/j.phrs.2020.104803 10.1016/j.jcin.2014.06.023 10.1016/j.ahj.2007.11.018 10.1016/j.atherosclerosis.2020.09.008 10.1371/journal.pone.0171682 10.1016/S0140-6736(08)61240-4 10.1016/j.amjcard.2020.09.012 10.4137/CMC.S4324 10.1001/jama.285.13.1711 10.1253/circj.CJ-10-0658 10.20996/1819-6446-2013-9-1-4-14 10.1056/NEJMoa040583 10.1038/s41591-020-0968-3 10.1016/j.tcm.2019.01.001 10.1016/j.cmet.2020.06.015 10.1016/j.dsx.2020.08.023 10.1016/j.jacc.2014.02.615 10.1016/j.jacc.2013.03.058 10.2165/00002512-200825080-00003 10.3810/psm.2010.06.1797 10.1093/eurheartj/ehx144 |
ContentType | Journal Article |
DBID | AAYXX CITATION ADTOC UNPAY DOA |
DOI | 10.21518/2307-1109-2021-11-2-56-75 |
DatabaseName | CrossRef Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2658-5952 |
EndPage | 75 |
ExternalDocumentID | oai_doaj_org_article_6aa0e9275c88428d841ee99af5366869 10.21518/2307-1109-2021-11-2-56-75 10_21518_2307_1109_2021_11_2_56_75 |
GroupedDBID | AAYXX ALMA_UNASSIGNED_HOLDINGS CITATION GROUPED_DOAJ ADTOC UNPAY |
ID | FETCH-LOGICAL-c1695-9dd160f2728d1000c6973c0b5aebe086ac410a84b6f590eb2557b648ac9c177b3 |
IEDL.DBID | DOA |
ISSN | 2307-1109 2658-5952 |
IngestDate | Wed Aug 27 01:30:46 EDT 2025 Tue Aug 19 21:13:39 EDT 2025 Tue Jul 01 01:18:58 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English Russian |
License | https://www.aterotromboz.ru/jour/about/editorialPolicies#openAccessPolicy cc-by-nc-nd |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1695-9dd160f2728d1000c6973c0b5aebe086ac410a84b6f590eb2557b648ac9c177b3 |
ORCID | 0000-0002-1518-6552 0000-0002-0316-2940 0000-0002-3617-9343 0000-0001-9685-4569 |
OpenAccessLink | https://doaj.org/article/6aa0e9275c88428d841ee99af5366869 |
PageCount | 20 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6aa0e9275c88428d841ee99af5366869 unpaywall_primary_10_21518_2307_1109_2021_11_2_56_75 crossref_primary_10_21518_2307_1109_2021_11_2_56_75 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-01-21 |
PublicationDateYYYYMMDD | 2022-01-21 |
PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-21 day: 21 |
PublicationDecade | 2020 |
PublicationTitle | Aterotromboz (Online) |
PublicationYear | 2022 |
Publisher | REMEDIUM GROUP» Ltd |
Publisher_xml | – name: REMEDIUM GROUP» Ltd |
References | ref13 ref35 ref12 ref34 ref15 ref37 ref14 ref36 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref39 ref16 ref38 ref19 ref18 ref24 ref46 ref23 ref45 ref26 ref25 ref47 ref20 ref42 ref41 ref22 ref44 ref21 ref43 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 |
References_xml | – ident: ref2 doi: 10.1093/eurheartj/ehz455 – ident: ref37 – ident: ref29 doi: 10.1001/jama.291.9.1071 – ident: ref1 – ident: ref3 – ident: ref5 – ident: ref8 doi: 10.1093/ehjcvp/pvw006 – ident: ref7 doi: 10.21518/2079-701X-2020-14-26-32 – ident: ref17 doi: 10.1185/030079903125002405 – ident: ref34 doi: 10.1056/NEJMoa0706201 – ident: ref6 doi: 10.1093/eurheartj/ehw272 – ident: ref22 doi: 10.1016/j.ijcard.2008.06.055 – ident: ref25 – ident: ref15 doi: 10.1016/j.jacc.2005.03.077 – ident: ref9 doi: 10.1016/S0140-6736(05)67394-1 – ident: ref20 doi: 10.1097/HJR.0b013e3283316ce8 – ident: ref43 doi: 10.1016/j.amjcard.2020.08.004 – ident: ref36 doi: 10.1056/NEJMoa0810177 – ident: ref18 doi: 10.1007/s11239-014-1142-x – ident: ref16 doi: 10.1007/s11883-014-0420-6 – ident: ref13 doi: 10.1016/j.jacc.2005.04.064 – ident: ref21 doi: 10.1016/j.acvd.2008.05.010 – ident: ref46 doi: 10.15829/1728-8800-2016-4-29-37 – ident: ref28 doi: 10.1056/NEJMoa1110874 – ident: ref23 doi: 10.1007/s10557-010-6224-1 – ident: ref38 – ident: ref39 doi: 10.1016/j.phrs.2020.104803 – ident: ref26 doi: 10.1016/j.jcin.2014.06.023 – ident: ref33 doi: 10.1016/j.ahj.2007.11.018 – ident: ref45 doi: 10.1016/j.atherosclerosis.2020.09.008 – ident: ref24 doi: 10.1371/journal.pone.0171682 – ident: ref35 doi: 10.1016/S0140-6736(08)61240-4 – ident: ref42 doi: 10.1016/j.amjcard.2020.09.012 – ident: ref10 doi: 10.4137/CMC.S4324 – ident: ref11 doi: 10.1001/jama.285.13.1711 – ident: ref31 doi: 10.1253/circj.CJ-10-0658 – ident: ref47 doi: 10.20996/1819-6446-2013-9-1-4-14 – ident: ref12 doi: 10.1056/NEJMoa040583 – ident: ref40 doi: 10.1038/s41591-020-0968-3 – ident: ref27 doi: 10.1016/j.tcm.2019.01.001 – ident: ref41 doi: 10.1016/j.cmet.2020.06.015 – ident: ref44 doi: 10.1016/j.dsx.2020.08.023 – ident: ref14 doi: 10.1016/j.jacc.2014.02.615 – ident: ref30 doi: 10.1016/j.jacc.2013.03.058 – ident: ref19 doi: 10.2165/00002512-200825080-00003 – ident: ref32 doi: 10.3810/psm.2010.06.1797 – ident: ref4 doi: 10.1093/eurheartj/ehx144 |
SSID | ssib027829645 ssib050729223 ssj0002910378 |
Score | 2.1740174 |
Snippet | According to the latest international and Russian guidelines for the treatment of dyslipidemias, statins are defined as the main group of drugs that... |
SourceID | doaj unpaywall crossref |
SourceType | Open Website Open Access Repository Index Database |
StartPage | 56 |
SubjectTerms | covid-19 dyslipidemia extreme cardiovascular risk low-density lipoprotein cholesterol (ldl-c) rosuvastatin very high cardiovascular risk |
SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZgK_E48EYsL_nANZvEiV_HglpVSK04sFLhYvkVVLUkqzQBpf-Cf8xMkq623Ogtiexx7G-c8cQznwn5UADGnsWYCF7pBCyeSFQJt6rwuQhgssSYC3N8Io7W5edTfrpz1BeGVcIiq226tvnpmqtV26c4quk8kGlADvnGhhRsdcqkukv2BO4tLcje-uTL_rfxMDkkPszH8A4GFjbhmrOJcBQNnEq3BUBHWI6ZZeCQiQRjDXeM08jh_5Dc7-uNHX7bi4sdw3P4mHy_fuUp3uR81Xdu5a_-YXO8VZ-ekEfzcpTuT0WekjuxfkbuHc8b7s_Jn4ORYgLzM2lTUSQ3Ts6mqPduoFPy1kDxZy6FHvW_LCYondUUlsL0En3tYNuBbmaeqKZGIf5GCCy9EdROoe5M9Xo5ibUUJtswtkwxDv4FWR8efP10lMynOCSANh4EGUIusopJpgJuJnihZeEzxy3oDzhU1pd5ZlXpRMV1Bo4-59KJUlmvfS6lK16SRd3U8RWhDr0tkMCEtvjtAUGlldqGSkQeK7ckxTV8ZjORdRhwckbQDYJuEHSDoMOVYYYLI_mSfESktzWQcHt80LQ_zAyREdZmUTPJvVLgsQVV5jFqbSteCKGEXpJyqyf_0fbr21V7Qx4wTMPIQHPzt2TRtX18B4ujzr2fp8FfzD8KaQ priority: 102 providerName: Unpaywall |
Title | Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk |
URI | https://www.aterotromboz.ru/jour/article/download/256/278 https://doaj.org/article/6aa0e9275c88428d841ee99af5366869 |
UnpaywallVersion | publishedVersion |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2658-5952 dateEnd: 20241231 omitProxy: true ssIdentifier: ssj0002910378 issn: 2658-5952 databaseCode: DOA dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2658-5952 dateEnd: 99991231 omitProxy: true ssIdentifier: ssib050729223 issn: 2307-1109 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NS_QwEA6ioL4H8RPXL3LwWmzTZpocVVZEWPHggp5CmqYgSHdZd5Ve3v_w_uN3Jq1LPYngpbSBZGieaWammXnC2HmKGDvhfQSy0hFaPIhUho8qdQmUaLIg1MKM7uF2nN09yafeUV-UE9bSA7cTdwHWxl6LXDql0FUuVZZ4r7WtZAqgIJTuoRnrBVOoSQLtnu7tr0nix_40hLRGC031ceG4usCSmMS6ZSQlC6gulo2oRCKh0jOM2CCiZMSe9Qok_3_YxqKe2ubDvr72LNPNNtvqXEp-2b7KDluZLXbZ-qjbNN9j_4aBJoJqLPmk4kRQHL20mevzhrcFWA2nH7IchS7eLRUZvdQc3Vn-RvFyaWcNn3ZcT5OaBnFf0lj5l8R0jn07uta3dljL8YNpgmROuez7bHwzfLy-jbqTGCJEjA5zLMsE4krkCABtCDjQeeriQlrUAQyKrMuS2KqsgErqGIN1KfMCMmWddkmeF-kBW60ntT9kvKCICUcQoC2tHzhQZnNtywq89FUxYOnnDJtpS7hhMFAJuBjCxRAuhnDBOyOMBJPLAbsiMJY9iDQ7NKAqmU6VzHeqNGDZEsofyD76DdnHbFNQYUWMqpacsNX5bOFP0d2ZF2dBs_E6-js8Y2vj-4fL5_9IPvYa |
linkProvider | Directory of Open Access Journals |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZgK_E48EYsL_nANZvEiV_HglpVSK04sFLhYvkVVLUkqzQBpf-Cf8xMkq623Ogtiexx7G-c8cQznwn5UADGnsWYCF7pBCyeSFQJt6rwuQhgssSYC3N8Io7W5edTfrpz1BeGVcIiq226tvnpmqtV26c4quk8kGlADvnGhhRsdcqkukv2BO4tLcje-uTL_rfxMDkkPszH8A4GFjbhmrOJcBQNnEq3BUBHWI6ZZeCQiQRjDXeM08jh_5Dc7-uNHX7bi4sdw3P4mHy_fuUp3uR81Xdu5a_-YXO8VZ-ekEfzcpTuT0WekjuxfkbuHc8b7s_Jn4ORYgLzM2lTUSQ3Ts6mqPduoFPy1kDxZy6FHvW_LCYondUUlsL0En3tYNuBbmaeqKZGIf5GCCy9EdROoe5M9Xo5ibUUJtswtkwxDv4FWR8efP10lMynOCSANh4EGUIusopJpgJuJnihZeEzxy3oDzhU1pd5ZlXpRMV1Bo4-59KJUlmvfS6lK16SRd3U8RWhDr0tkMCEtvjtAUGlldqGSkQeK7ckxTV8ZjORdRhwckbQDYJuEHSDoMOVYYYLI_mSfESktzWQcHt80LQ_zAyREdZmUTPJvVLgsQVV5jFqbSteCKGEXpJyqyf_0fbr21V7Qx4wTMPIQHPzt2TRtX18B4ujzr2fp8FfzD8KaQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficiency+of+high-intensity+therapy+with+rosuvastatin+for+secondary+prevention+of+cardiovascular+complications+in+patients+with+a+very+high+risk&rft.jtitle=Aterotromboz+%28Online%29&rft.au=T.+E.+Kolmakova&rft.au=I.+A.+Alekseeva&rft.au=N.+A.+Tmoyan&rft.au=M.+V.+Ezhov&rft.date=2022-01-21&rft.pub=REMEDIUM+GROUP%C2%BB+Ltd&rft.issn=2307-1109&rft.eissn=2658-5952&rft.volume=11&rft.issue=2&rft.spage=56&rft.epage=75&rft_id=info:doi/10.21518%2F2307-1109-2021-11-2-56-75&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_6aa0e9275c88428d841ee99af5366869 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2307-1109&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2307-1109&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2307-1109&client=summon |